Nektar Therapeutics: Files For Mixed Shelf Offering Of Up To $300M

+0.90%

Nektar Therapeutics

NKTR

0.00

- SEC Filing

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

Assessing Nektar Therapeutics (NKTR) Valuation Following Recent Share Price Surge

We Think Gelteq (NASDAQ:GELS) Has A Fair Chunk Of Debt

UPDATE 1-Novo Nordisk says Alzheimer's drug trial fails to meet main goal

EXCLUSIVE: Enlivex Therapeutics Tells Benzinga 'Enlivex to continue clinical development of Allocetra TM, a potentially game-changing knee osteoarthritis therapeutic, a growing market with significant unmet medical need'

US STOCKS-Wall Street futures mixed as markets hunt clues on imminent Fed move

Guggenheim Initiates Coverage On Adagene with Buy Rating, Announces Price Target of $9

Barclays Maintains Overweight on Kura Oncology, Raises Price Target to $28

How Investors May Respond To Nektar Therapeutics (NKTR) Clinical Progress and Leadership Transition